

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/586,426
Filing Date	July 19, 2006
First Named Inventor	Mark R. Bush, et al
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	PC25862A

Sheet 1 of 3

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 3,983,140	09-28-1976	Endo, et al	
		US- 4,049,495	09-20-1977	Endo, et al	
		US- 4,137,322	01-30-1979	Endo, et al	
		US- 4,198,425	04-15-1980	Mistui, et al	
		US- 4,255,444	03-10-1981	Oka, et al	
		US- 4,262,013	04-14-1981	Mistui, et al	
		US- 4,681,893	07-21-1987	Roth	
		US- 4,808,607	02-28-1989	Wareing	
		US- 4,968,681	11-06-1990	Hubsch, et al	
		US- 5,273,995	12-28-1993	Roth	
		US- 5,969,156	10-19-1999	Briggs, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7*
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 300 278	01-25-1989	Hubsch, et al		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/586,426
Filing Date	July 19, 2006
First Named Inventor	Mark R. Bush, et al
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	PC25862A

Sheet	2	of	3
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Brown, M., et al, "Lowering Plasma Cholesterol by Raising LDL Receptors", The New England Journal of Medicine, Vol. 305, No. 9; (1981); pp 515-517	
		"The Lipid Research Clinics Coronary Primary Prevention Trial Results I. Reduction in Incidence of Coronary Heart Disease", JAMA, Vol. 251, (1984); pp 351-374	
		Singer, F., et al, "New Inhibitors of in vitro Conversion of Acetate and Mevalonate to Cholesterol (25525)", P.S. E.B.M., Vol. 102, (1958); pp 370-373	
		Hulcher, Frank E., "Inhibition of Hepatic Cholesterol Biosynthesis by 3,5-Dihydroxy-3,4,4-Trimethylvaleric Acid and Its Site of Action", Archives of Biochemistry and Biophysics, Vol. 146, (1971); pp 422-427	
		Brown, A., et al, "Crystal and Molecular Structure of Compaction, A New Antifungal Metabolite from <i>Penicillium brevicompactum</i> ", J. Chem. Soc. Perkin, (1976); pp 1165-1170	
		McTaggart, F., et al, "Preclinical and Clinical Pharmacology of Rosuvastatin, a New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor", Am J Cardiol, Vol. 87(suppl), (2001); pp 28B-32B	
		Chapman, M. et al, "Optimizing the pharmacology of statins: characteristics of rosuvastatin", Atherosclerosis Supplements 2 (2002); pp 33-37	
		Bottoroff, M., et al, "Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors", Arch Intern Med., Vol 160, (2000); pp 2273-2280	
		Beard, Sandra L., "HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety Profiles", Journal of the American Pharmaceutical Association, Vol. 40, No. 5, (2000); pp 637-644	
		Takemoto, M., et al, "Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors", Atheroscler Thromb Vasc Biol, Vol. 21, (2001); pp 1712-1719	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/586,426		
		Filing Date	July 19, 2006		
		First Named Inventor	Mark R. Bush, et al		
		Art Unit	1614		
		Examiner Name	Unknown		
Sheet	3	of	3	Attorney Docket Number	PC25862A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Ansell, B., et al, "hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels", Heart Disease, Vol. 5, (2003) pp 2-7		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.